Tag: Drug Development
-
Vasomune expands with AnGes partnership to broaden vascular damage therapy indications
Vasomune and AnGes announce expanded collaboration The Sunnybrook-based start-up Vasomune Therapeutics has strengthened its strategic alliance with Japanese biopharma company AnGes. The expanded partnership aims to broaden the indications for Vasomune’s lead drug candidate, which targets vascular damage and related cardiovascular conditions. The agreement comes with a $4 million funding commitment designed to accelerate development…
-
Vasomune and AnGes Expand Vascular Drug Indications Partnership
Partnership Overview Sunnybrook-based start-up Vasomune Therapeutics has announced an expanded collaboration with the Japanese biopharma company AnGes to broaden the indications for their vascular damage treatment candidate. The agreement will extend the reach of the collaboration beyond its initial scope, enabling further development and validation across additional vascular conditions. The expanded partnership comes with a…
-
MS Research Derailed by Stock Market Spoofing: A CEO-Led Lawsuit Exposes Market Manipulation
Introduction: When Market Manipulation Hits the Lab In the high-stakes world of biotechnology, scientific breakthroughs depend on steady funding, predictable stock performance, and transparent markets. A recent lawsuit filed by a Canadian biotech firm alleges that a practice known as stock spoofing—where traders place and cancel orders to mislead others about supply and demand—undermined investor…
-
Adalyon appoints Ulrik Zeuthen as CEO to drive next phase
Adalyon Announces CEO Appointment to Lead the Next Phase of Growth Adalyon, a Finnish biotech-tech firm focused on transforming clinical drug development through AI-powered speech biomarker technology, today announced the appointment of Ulrik Zeuthen as Chief Executive Officer. The leadership change signals the company’s commitment to accelerating product development, expanding strategic partnerships, and delivering on…
-
Bezuclastinib Peaks in GIST: Positive PEAK Phase 3 Results for KIT Exon 17/18 Mutants
New Phase 3 data positions Bezuclastinib as a potential new standard for KIT Exon 17/18 mutant GIST In a pivotal development for patients with advanced gastrointestinal stromal tumors (GISTs), Bezuclastinib demonstrated positive outcomes in the PEAK Phase 3 study focusing on KIT exon 17/18 mutant disease. GISTs are driven by complex mutations in the KIT…
-
Drugs Without Nausea: Scientists Target Brain to Separate Side Effects
Overview: Aiming to keep the appetite, not the nausea Nausea is a common hurdle for millions using modern weight-loss medications, from GLP-1 receptor agonists to newer formulations. As scientists race to expand the benefits of these drugs, a central question guides the research: can the brain’s pathways be fine-tuned so that the appetite-suppressing effects remain,…
-
BioLineRx Wins USPTO Allowance for GLIX1 Cancer Therapy Patent
BioLineRx Announces USPTO Notice of Allowance for GLIX1 Patent BioLineRx has announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for a key patent covering the company’s GLIX1 program. This milestone strengthens the intellectual property framework around GLIX1, a molecule aimed at treating a broad range of cancers.…
-
New diabetes drug may curb complications beyond blood sugar control, study hints
Overview: A potential breakthrough beyond managing blood sugar Researchers are exploring a new drug candidate that could help prevent some of the most troublesome complications of diabetes, even when blood sugar control remains challenging. Early laboratory studies in mice and human cells suggest that this experimental compound targets inflammatory processes and tissue repair pathways that…
-
New Drug Could Prevent Diabetes Complications Beyond Blood Sugar
Summary: A potential breakthrough in diabetes care A new experimental drug compound may help prevent and treat some of the most challenging complications of diabetes—such as impaired wound healing and widespread inflammation—by acting independently of blood sugar levels. Researchers conducted tests in mice and human cell models, and early results suggest the drug could complement…
-
A New Drug Shields Mitochondria to Prevent Kidney Injury in Mice
Researchers unveil a mitochondria-focused approach to preventing kidney injury Acute kidney injury (AKI) remains a serious and sometimes fatal complication in hospitalized patients, especially those facing sepsis, major surgery, or intensive care treatments. A new preclinical study from researchers at the University of Utah Health suggests a novel drug can protect kidney cells by preserving…